UPFRONT MOLECULAR TARGETED THERAPY FOR THE TREATMENT OF BRAF-MUTANT PEDIATRIC HIGH-GRADE GLIOMA
NEURO-ONCOLOGY(2022)
Abstract
Upfront targeted therapy for patients with BRAF-mutant pHGG is feasible and effective, with superior clinical outcomes compared to historical data. This promising treatment paradigm is currently being evaluated prospectively in the Children's Oncology Group ACNS1723 clinical trial.
MoreTranslated text
Key words
BRAF,high-grade glioma,pediatrics,targeted therapy,treatment outcome
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined